Japan’s Otsuka to stop development of Alzheimer’s disease drug

May 22 (Reuters) – Japan’s Otsuka Pharmaceutical said on Wednesday it would stop developing an experimental drug to treat agitation and restlessness caused by symptoms of Alzheimer’s disease.
 
The drug candidate, AVP-786, failed to show statistically significant improvement of agitation associated with Alzheimer’s dementia in a late-stage study, Otsuka said.
 
Alzheimer’s is a progressive brain disorder which causes a decline in memory, thinking, learning and organizing skills. The disease is the most common type of dementia.
 
Agitation associated with dementia has a large impact on the quality of life for the patients, and is reported in about half of all patients with Alzheimer’s dementia, according to Otsuka.
 
Otsuka Pharmaceutical’s parent Otsuka Holdings (4578.T) is mainly engaged in the medical and nutraceuticals related business.

Source: Reuters

/by
You might also like
BiogenRare success for Alzheimer’s research unlocks hope for future therapies
amyloid oligomersEisai, Biogen launch rolling BLA for subcutaneous Alzheimer’s therapy Leqembi
LeqembiMajor US health systems expect to offer Alzheimer’s drug Leqembi in a few months
LeqembiBridgeBio Pharma’s heart disease drug meets main goal in late-stage study
LeqembiAlzheimer’s Association lobbies for Medicare coverage of Leqembi and other drugs
RocheBiogen-Lilly solidly in the lead after Roche’s Alzheimer’s Drug misses in Phase III
LeqembiBioXcel to cut over 50% of jobs as it pivots focus to agitation drug
LeqembiEuropean Alzheimer’s experts unconvinced by new Eisai, Biogen drug